維利西呱是一種口服的可溶性鳥苷酸環(huán)化酶激活劑，用于治療惡性慢性心力衰竭和左心室射血分數(shù)（LVEF）降低的患者。其通過一氧化氮–環(huán)鳥苷酸–蛋白激酶（NO-cGMP-PK）信號通路新機制，改善心肌收縮性，從而治療心力衰竭。臨床研究表明，維利西呱對慢性心力衰竭和LVEF降低的患者雖不能顯著改善12周后NT-proBNP水平，但有降低NT-proBNP水平，改善LVEF和降低不良反應事件的趨勢，同時該藥物耐受性較好，具有很好的安全性。

vericiguat is an oral soluble guanylate cyclase activator, is used in treatment of patients with malignant chronic heart failure and decreased left ventricular ejection fraction (LVEF). vericiguat can improve myocardial contractility and treat heart failure through the new mechanism of nitric oxide-cyclic guanosine monophosphate-protein kinase (NO-cGMP-PK) signaling pathway. Clinical studies have shown that although vericiguat can not significantly improve the NT-proBNP level after treatment for 12 weeks for patients with malignant chronic heart failure and decreased (LVEF), there is a trend of decreasing NT-proBNP level, improving LVEF, and decreasing adverse events. At the same time vericiguat has better tolerance with good security.